UNICA IRIS Institutional Research Information System

BARCELLONA, DORIS
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 121.656
NA - Nord America 6.635
AS - Asia 2.587
SA - Sud America 637
AF - Africa 114
OC - Oceania 56
Continente sconosciuto - Info sul continente non disponibili 5
Totale 131.690
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 119.842
US - Stati Uniti d'America 6.500
SG - Singapore 957
CN - Cina 859
BR - Brasile 516
SE - Svezia 435
GB - Regno Unito 297
DE - Germania 271
UA - Ucraina 253
VN - Vietnam 244
FI - Finlandia 127
IN - India 86
CA - Canada 79
NL - Olanda 74
HK - Hong Kong 66
FR - Francia 62
KR - Corea 62
AU - Australia 45
AR - Argentina 41
IE - Irlanda 38
AT - Austria 37
JP - Giappone 37
ES - Italia 36
MX - Messico 36
TR - Turchia 36
IR - Iran 34
PL - Polonia 33
ZA - Sudafrica 33
BD - Bangladesh 31
EG - Egitto 26
ID - Indonesia 26
RU - Federazione Russa 22
CO - Colombia 20
IQ - Iraq 20
EC - Ecuador 19
MA - Marocco 19
DK - Danimarca 18
PK - Pakistan 18
BE - Belgio 17
TW - Taiwan 15
MY - Malesia 14
CH - Svizzera 13
KE - Kenya 13
PH - Filippine 13
PY - Paraguay 12
UZ - Uzbekistan 12
CZ - Repubblica Ceca 11
LT - Lituania 11
NZ - Nuova Zelanda 11
BG - Bulgaria 9
CL - Cile 8
HU - Ungheria 8
PE - Perù 8
SD - Sudan 8
RO - Romania 6
TH - Thailandia 6
AE - Emirati Arabi Uniti 5
ET - Etiopia 5
IL - Israele 5
NO - Norvegia 5
SA - Arabia Saudita 5
CY - Cipro 4
JO - Giordania 4
PA - Panama 4
PT - Portogallo 4
VE - Venezuela 4
BY - Bielorussia 3
CR - Costa Rica 3
DZ - Algeria 3
EU - Europa 3
GY - Guiana 3
KW - Kuwait 3
KZ - Kazakistan 3
LK - Sri Lanka 3
LU - Lussemburgo 3
MT - Malta 3
NP - Nepal 3
PR - Porto Rico 3
SK - Slovacchia (Repubblica Slovacca) 3
UY - Uruguay 3
AZ - Azerbaigian 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GF - Guiana Francese 2
GR - Grecia 2
HR - Croazia 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
OM - Oman 2
RS - Serbia 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
AM - Armenia 1
AN - Antille olandesi 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
Totale 131.671
Salva come PNG Salva come JPEG
Città #
Cagliari 113.896
Uta 5.371
Fairfield 765
Ashburn 589
Woodbridge 526
Dallas 492
Houston 401
Singapore 373
Boardman 309
Seattle 305
Nyköping 296
Chandler 293
Wilmington 287
Cambridge 258
Ann Arbor 246
Beijing 217
Jacksonville 132
Los Angeles 110
Santa Clara 105
Shanghai 96
Dearborn 93
Boston 83
New York 81
Helsinki 71
The Dalles 67
Ho Chi Minh City 64
Buffalo 63
Dong Ket 58
San Diego 56
Nanjing 51
Rome 51
São Paulo 49
Hong Kong 48
Seoul 47
Hefei 46
Munich 46
Redwood City 42
Hanoi 41
Redondo Beach 38
Milan 36
Nuremberg 35
Chicago 32
Guangzhou 27
Toronto 27
Dublin 26
London 26
Frankfurt am Main 25
Shenyang 24
Warsaw 24
Vienna 23
Brandenburg 20
Stockholm 20
Johannesburg 19
Atlanta 18
Hebei 18
Phoenix 18
Tokyo 18
Rio de Janeiro 17
Tianjin 17
Turku 17
Amsterdam 16
College Station 16
Nanchang 16
Ankara 15
Brussels 15
Redmond 15
Sydney 15
Brooklyn 14
Central 14
Denver 14
Jiaxing 14
Salt Lake City 14
Sassari 14
Changsha 13
Mountain View 13
Nairobi 12
Selargius 12
Tashkent 12
Bogotá 11
Chennai 11
Delhi 11
Norwalk 11
Orange 11
Wuhan 11
Belo Horizonte 10
Lahore 10
Mexico City 10
Montreal 10
Mumbai 10
Perth 10
Taipei 10
Curitiba 9
Manchester 9
Quartu Sant'elena 9
San Francisco 9
Acate 8
Biên Hòa 8
Campinas 8
Jakarta 8
Juiz de Fora 8
Totale 127.115
Salva come PNG Salva come JPEG
Nome #
Abnormal lipid accumulation and cluster formation of naive peripheral blood mononuclear cells: a useful tool for early detection of central nervous system damage in elderly 2.842
Heterogeneity of Antiphospholipid Syndrome (APS) as Characterized by Brain Perfusion Techniques. Towards New Ways of Syndrome Characterization 2.750
The venous thromboembolic risk and the clot wave analysis: a useful relationship? 2.729
Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review 2.715
Myocardial infarction and Antiphospholipid Syndrome: A first study on finger PPG waveforms effects 2.547
Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. 2.532
Olanzapine-associated portal and superior mesenteric vein thrombosis 2.487
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.400
Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home 2.297
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.264
Empathy and the Educational Approach to Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants 2.154
Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al 2.145
Management of Patients Taking Oral Anticoagulants Who Need Urgent Surgery for Hip Fracture 2.119
Pulmonary Thrombosis: A Clinical Pathological Entity Distinct from Pulmonary Embolism? 2.057
Multiple specialized stem cell niches characterize hematopoiesis in the human fetal liver 2.054
A Sardinian Family with Factor XI Deficiency 1.974
Clot Waveform Analysis: From Hypercoagulability to Hypocoagulability - A Review 1.970
Ultrastructural findings of lung injury due to Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study 1.905
A “Catastrophic” Heparin-Induced Thrombocytopenia 1.857
Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptic case and review of the literature 1.786
Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? 1.784
The hemostatic system. 1st Part 1.769
Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review 1.692
Point-of-care testing INR: an overview 1.654
Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No 1.640
Pulmonary thrombosis in 2019-nCoV pneumonia? 1.636
Risk of reoperation in bioprosthetic valve patients with indication for longterm anticoagulation. Results from the observational retrospective multicentre PLECTRUM study 1.634
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 1.577
Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants 1.567
Direct oral anticoagulants: what can we learn? 1.556
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study 1.554
Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes 1.542
Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly With Rheumatoid Arthritis. Identification of Risk Factors 1.494
The criteria of the Italian Federation of Thrombosis Centres on DOACs: a ‘‘real world’’ application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist 1.453
Thrombosis centres and AVKs monitoring in COVID-19 pandemic 1.430
Allele 4G of gene PAI-I associated with prothrombin mutation G20210A increases the risk for venous thrombosis 1.426
Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants 1.379
Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? 1.342
Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills 1.320
A guide to oral anticoagulation 1.300
Findings from a multicentre, observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry 1.298
Portable coagulometer for vitamin K-antagonist monitoring: the patients’ point of view 1.269
The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders 1.251
The Italian START-Register on anticoagulation with focus on atrial fibrillation 1.246
Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? 1.236
Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists 1.224
A ‘‘two-step’’ educational approach for patients taking oral anticoagulants does not improve therapy control 1.197
Heparins and 2019-nCoV infection: a narrative review 1.190
Thyroid disorders and hypocoagulability 1.166
The predictive ability of bleeding risk stratification models in very old patients on vitaminK antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 1.160
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome 1.122
Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism 1.120
High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice 1.091
A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant 1.055
Rheumatoid arthritis and thrombosis 1.050
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 1.050
Association of Antiplatelet and Anticoagulant Treatment in Patients with Mechanical Prosthetic Heart Valves. Data from the Observational Multicentre PLECTRUM Study 1.049
Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA) 1.041
Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? 1.028
Liver changes in Wilson’s disease: The full spectrum. A report of 127 biopsies from 43 patients 1.023
Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? 978
Fetal programming of COVID-19: May the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? 957
Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study 949
Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review 943
Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell’Emostasi e della Trombosi (SISET) 898
null 845
Aortic vulnerability to COVID-19: Is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature 840
Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: The evidence from histology and scanning electron microscopy 830
null 824
Managing anticoagulation in the COVID-19 era between lockdown and reopening phases 818
Management of DOAC in patients undergoing planned surgery or invasive procedure: FCSA position paper 805
Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk 802
Scanning electron microscopy of lung disease due to COVID-19 – a case report and a review of the literature 797
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 794
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 791
null 789
Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab 779
null 772
Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk 763
Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants 737
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET 720
Comparison of anticoagulation quality between acenocoumarol and warfarin in patients with mechanical prosthetic heart valves: Insights from the nationwide PLECTRUM study 700
null 679
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation 675
null 644
null 633
null 617
null 616
null 579
null 573
null 547
null 491
Over-anticoagulation by vitamin K antagonists and gender differences 447
null 440
null 436
Hormones and thrombosis: the dark side of the moon 411
Contraceptives and Thrombosis: An Intertwined Revolutionary Road 407
Performance and Interpretation of Clot Waveform Analysis 389
Why Does Rivaroxaban Not Work in Severe Mitral Stenosis? 366
Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? 358
Totale 126.638
Salva come PNG Salva come JPEG
Categoria #
all - tutte 172.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 172.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112.333 0 0 0 0 0 3.063 2.213 1.693 649 1.850 1.625 1.240
2021/20228.985 796 650 357 537 721 713 592 531 736 1.001 1.211 1.140
2022/202313.417 1.236 1.862 1.850 1.246 1.120 1.337 652 821 814 790 1.040 649
2023/202413.891 477 803 541 950 1.432 2.101 2.368 987 653 891 1.330 1.358
2024/202530.870 6.693 8.203 5.303 2.881 2.608 1.761 2.023 130 332 427 212 297
2025/20263.163 491 285 1.012 704 625 46 0 0 0 0 0 0
Totale 132.160